FBR 001
Alternative Names: FBR-001; Mers-CoV (FBR-001)Latest Information Update: 28 Aug 2020
At a glance
- Originator Fabentech
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Middle East respiratory syndrome coronavirus
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in France (Parenteral)
- 22 Jul 2016 Early research in Middle East respiratory syndrome coronavirus (Prevention) in France (Parenteral)
Development Overview
Introduction
Fabentech is developing a vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV), designated FBR 001, in early research stage in France.
FBR 001 is a passive immunotherapy comprising administration of F(ab')2 fragments of specific equine polyclonal immunoglobulins against the Middle East respiratory syndrome coronavirus (MERS-CoV).
As at August 2020, no recent reports of development had been identified for research development in Middle-East-respiratory-syndrome-coronavirus (Prevention) in France (Parenteral).
Key Development Milestones
Fabentech is conducting early research studies with FBR 001 in France.
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class COVID-19 vaccines, Viral vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B (Viral Vaccines)
-
EPhMRA code
J7A (Pure Vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Middle East respiratory syndrome coronavirus | - | Prevention | No development reported (Research) | France | Parenteral / unspecified | Fabentech | 28 Aug 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Fabentech | Originator | France |
| Fabentech | Owner | France |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Aug 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in France (Parenteral) Updated 28 Aug 2020 |
| 22 Jul 2016 | Phase Change | Early research in Middle East respiratory syndrome coronavirus (Prevention) in France (Parenteral) Updated 22 Jul 2016 |
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG